| Daniel P Geis, MD | |
|
250 Park St, Bowling Green, KY 42101-1760 | |
| (270) 745-1332 | |
| (270) 745-1323 |
| Full Name | Daniel P Geis |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 37 Years |
| Location | 250 Park St, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093707747 | NPI | - | NPPES |
| 64295140 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 29514 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bowling Green Associated Pathologists Psc | 3870584279 | 3 |
News Archive
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
Advances in medical technology are a main factor driving the trend of increasing health care costs, and industry stakeholders agree that improved evaluation methods are needed to better measure the benefits and risks of new technologies and procedures in order to avoid misallocation of health care dollars.
Ramot at Tel Aviv University has signed a collaboration agreement with Bayer to develop and validate a platform for in vitro cardiotoxicity screening, using human heart tissues 3D-printed in Prof. Tal Dvir's Laboratory for Tissue Engineering and Regenerative Medicine at Tel Aviv University.
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.
› Verified 8 days ago
| Entity Name | Bowling Green Associated Pathologists Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285664946 PECOS PAC ID: 3870584279 Enrollment ID: O20040524000719 |
News Archive
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
Advances in medical technology are a main factor driving the trend of increasing health care costs, and industry stakeholders agree that improved evaluation methods are needed to better measure the benefits and risks of new technologies and procedures in order to avoid misallocation of health care dollars.
Ramot at Tel Aviv University has signed a collaboration agreement with Bayer to develop and validate a platform for in vitro cardiotoxicity screening, using human heart tissues 3D-printed in Prof. Tal Dvir's Laboratory for Tissue Engineering and Regenerative Medicine at Tel Aviv University.
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel P Geis, MD Po Box 9961, Bowling Green, KY 42102-4961 Ph: (270) 745-1467 | Daniel P Geis, MD 250 Park St, Bowling Green, KY 42101-1760 Ph: (270) 745-1332 |
News Archive
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
Advances in medical technology are a main factor driving the trend of increasing health care costs, and industry stakeholders agree that improved evaluation methods are needed to better measure the benefits and risks of new technologies and procedures in order to avoid misallocation of health care dollars.
Ramot at Tel Aviv University has signed a collaboration agreement with Bayer to develop and validate a platform for in vitro cardiotoxicity screening, using human heart tissues 3D-printed in Prof. Tal Dvir's Laboratory for Tissue Engineering and Regenerative Medicine at Tel Aviv University.
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.
› Verified 8 days ago
Marie L. Michelson, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1323 Fax: 270-745-1332 | |
James F. Beattie, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1316 Fax: 270-745-1323 | |
Eugene Terry Tatum, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1316 Fax: 270-745-1323 | |
Devin Kia Sanders, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1316 |